Earnings Call · Q2 FY2025·2025-08-05

Q2 25EPS -17.14%·Rev n/aQ1 25EPS +3.85%·Rev n/aQ4 24EPS -27.16%·Rev n/aQ3 24EPS -3.03%·Rev n/a⚠ consensus missing

RECURSION PHARMACEUTICALS, INC. RXRX

Christopher C. Gibson — Co-Founder and CEO

Najat Khan — Chief Scientific Officer

Ben R. Taylor — Chief Financial Officer

−4.7%1d on move date−4.1% vs SPY3d−6.7%5d−8.8%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more RXRX calls or request research access.

More RXRX calls Browse calls Request research access